The Economist on Friday published two articles from Saturday's print edition regarding the XIX International AIDS Conference (AIDS 2012). One article states that "few areas of international affairs have seen more recent success than the fight against AIDS," and discusses advancements in HIV treatment research and availability.
From nurse education to bedside nursing, nursing is experiencing an electronic makeover. Eighty seven percent of nursing schools now use high-fidelity mannequins to bring various levels of simulation to their students. Prescriber orders, previously written on paper, are now entered into a comprehensive electronic ordering system.
A content analysis of newspaper stories about organ and tissue donation, conducted by researchers at the University at Buffalo, found an almost 4:1 ratio of positive-to-negative articles on the subject.
A comprehensive account of the most important advances in rheumatology research from the past decade has been published in BioMed Central's open access journal Arthritis Research and Therapy (AR&T). This freely available collection of 38 articles written by an internationally recognized group of experts spanning more than 400 pages is an essential educational tool which provides clinicians and researchers with a detailed overview of the current status of basic, translational and clinical research in rheumatology.
VOA News has published a five-part series examining U.N. Women. The agency's "success depends on availability of resources and financial support. Member states have agreed to provide the new entity with an initial minimum budget of at least $500 million a year," the news service writes.
eLife, the new open-access journal for outstanding scientific advancements, has published its first four research articles.
Global Post examines the quest for an effective vaccine to fight malaria. According to Global Post, "epidemiologists are pinning their hopes on a malaria vaccine" because "[k]illing mosquitoes, or avoiding bites, is an imprecise solution to malaria."
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrating that treatment with ACE-041, an inhibitor of signaling through the activin receptor-like kinase 1 receptor, slows tumor growth and progression by inhibiting angiogenesis.